Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I)
Xiangyan Ruan, Wenpei Bai, Mulan Ren, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 5
Open Access | Times Cited: 11

Showing 11 citing articles:

“MANAGEMENT OF MENOPAUSAL HOT FLUSHES” RECOMMENDATIONS OF SPANISH MENOPAUSE SOCIETY
María Fasero, M Sanchez, Laura Baquedano, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology X (2025) Vol. 25, pp. 100366-100366
Open Access | Times Cited: 2
Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial
Yu Qi, Fang Ming, Jiezhi Ma, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 5
Open Access | Times Cited: 9
Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis
Helen Michaela de Oliveira, César Antonio González-Díaz, Lívia Mirelle Barbosa, et al.
Maturitas (2025) Vol. 195, pp. 108220-108220
Closed Access
Menopause part I: Vasomotor symptoms (I)
Peng‐Hui Wang, Szu‐Ting Yang, Wen-Hsun Chang, et al.
Taiwanese Journal of Obstetrics and Gynecology (2025) Vol. 64, Iss. 2, pp. 230-238
Open Access
An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects
Yang Li, Yue Liu, Megumi Iwai, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 2243-2252
Open Access
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause
Megan Z. Roberts, Miranda Andrus
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1131-1136
Closed Access | Times Cited: 2
▼Fezolinetant for menopausal vasomotor symptoms

Drug and Therapeutics Bulletin (2024) Vol. 62, Iss. 8, pp. 118-124
Closed Access | Times Cited: 1
Breakthroughs in women's health for treating vasomotor symptoms
Peng‐Hui Wang, Wen-Ling Lee
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 6, pp. 814-816
Open Access | Times Cited: 1
Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause
Laura Cucinella, Sara Tedeschi, Stefano Memoli, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024), pp. 1-9
Closed Access
Reply to ‘Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring careful evaluation of the benefit-risk balance’
Megan Z. Roberts, Miranda Andrus
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 14, pp. 1973-1974
Closed Access
New Drug: Fezolinetant for moderate to severe vasomotor symptoms associated with menopause

Australian Prescriber (2024) Vol. 47, Iss. 5, pp. 162-163
Open Access
Page 1

Scroll to top